Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 1,101–1,200 of 1,689
Frequency of the apolipoprotein E ε2 allele is diminished in sporadic Alzheimer disease
West, H. L., William Rebeck, G., & Hyman, B. T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)91074-x · Cited by 125
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125
“Plasma levels of apoE and other lipids and lipoprot eins are under strong genetic influence by the APOE polymorphism defining the three apoE isoforms, and the ε4 allele is a strong genetic risk factor for Alzheimer disease[18-25].”
Lehtim�ki, T., Pirttil�, T., Mehta, P., Wisniewski, H., Frey, H., & Nikkari, T. (1995) · Human Genetics · doi:10.1007/bf00225071 · Cited by 125
“Most previous studies have shown an increased apoE4 frequency in late-onset AD patients (Corder et al. 1993; Noguchi et al. 1993; Poirier et al. 1993; Saunders et al. 1993).”
Berchtold, N. C., Sabbagh, M. N., Beach, T. G., Kim, R. C., Cribbs, D. H., & Cotman, C. W. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.031 · Cited by 124
Cognitive Performance in Older Women Relative to ApoE-ε4 Genotype and Aerobic Fitness
ETNIER, J. L., CASELLI, R. J., REIMAN, E. M., ALEXANDER, G. E., SIBLEY, B. A., TESSIER, D., & MCLEMORE, E. C. (2007) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000239399.85955.5e · Cited by 124
“A polipoprotein E (ApoE) genotype is an important risk factor for Alzheimer disease (AD) (13,33).”
BackgroundNakamura, T., Watanabe, A., Fujino, T., Hosono, T., & Michikawa, M. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-35 · Cited by 124
“Background It has been shown that the prevalence of Alzheimer's disease (AD) is associated with the polymorphisms of genes related to cholesterol metabolism, including apolipoprotein E (apoE) [1-3], ATP-binding cassette transporter A1 (ABCA1) [4], and CYP46, the gene encoding cholesterol 24-hydroxylase [5,6].”
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Marzolo, M.-P., & Bu, G. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.10.005 · Cited by 122
Cooper, J. M., Lathuiliere, A., Migliorini, M., Arai, A. L., Wani, M. M., Dujardin, S., Muratoglu, S. C., Hyman, B. T., & Strickland, D. K. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100715 · Cited by 122
“ApoE genotype has a strong impact on development of lateonset AD, with the ε4 allele representing a risk factor and the ε2 allele being protective (30, 31).”
BackgroundMorishima-Kawashima, M., Oshima, N., Ogata, H., Yamaguchi, H., Yoshimura, M., Sugihara, S., & Ihara, Y. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64847-x · Cited by 119
“Genetic linkage studies suggest that the e4 allele is a strong risk factor for late-onset Alzheimer’s disease (AD), and is associated with an earlier age of onset.(2,3) The potential role of the e4 allele in amyloid b-protein (Ab) deposition has thus been of particular interest, given the critical involvement of Ab in…”
BackgroundAccumulation of intraneuronal Aβ correlates with ApoE4 genotype
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., & Wirths, O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0666-1 · Cited by 120
“The e4 allele of the ApoE gene is the major known genetic risk factor for AD with a frequency of *15% in general populations but [50% in AD patients [16].”
BackgroundAβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease
Gearing, M., Mori, H., & Mirra, S. S. (1996) · Annals of Neurology · doi:10.1002/ana.410390320 · Cited by 120
Increased caveolin-1 expression in Alzheimer’s disease brain
Gaudreault, S. B., Dea, D., & Poirier, J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.07.004 · Cited by 120
“Patients with two ε4 alleles exhibit an earlier age of onset [4,38], higher amyloid levels and amyloid plaque counts [13,42], cerebrovascular amyloid [37] and a marked reduction in choline acetyltransferase [34,46] compared to non-ε4 allele AD subjects.”
BackgroundNeuroinflammation‐induced acceleration of amyloid deposition in the APPV717F transgenic mouse
Qiao, X., Cummins, D. J., & Paul, S. M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01666.x · Cited by 119
“Individuals who inherit one or two apoE4 alleles have a 3±10-fold increase in the ageadjusted relative risk for developing AD, two alleles producing a greater risk than one, and an earlier age of onset compared to those who inherit the more common E3 allele (Corder et al., 1993).”
BackgroundEwers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119
“Alzheimer's disease have shown that the ApoE-e4 genotype is associated with increased cholesterol levels in both blood (Corder et al., 1993; Notkola et al., 1998) and CSF as measured by the metabolite 24S-hydroxycholesterol (Papassotiropoulos et al., 2002; Leoni et al., 2006).”
BackgroundFitz, N. F., Cronican, A. A., Saleem, M., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1937-12.2012 · Cited by 119
“It is important to note that, while the incidence of AD among APOE4 allele carriers is substantially increased, not everybody with this allele develops the disease (Corder et al., 1993).”
BackgroundBehavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse
Anderson, R., Barnes, J. C., Bliss, T. V. P., Cain, D. P., Cambon, K., Davies, H. A., Errington, M. L., Fellows, L. A., Gray, R. A., Hoh, T., et al. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00598-8 · Cited by 119
Nelson, M. R., Liu, P., Agrawal, A., Yip, O., Blumenfeld, J., Traglia, M., Kim, M. J., Koutsodendris, N., Rao, A., Grone, B., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01480-8 · Cited by 120
“As APOE4 carriers make up 55–75% of AD cases 17–20 , there is a critical need to investigate the roles of APOE4 in AD pathogenesis and to identify protective targets to mitigate its detrimental effects.”
BackgroundAn inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease
Roses, A. D. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.88 · Cited by 118
Self-citationLiraz, O., Boehm-Cagan, A., & Michaelson, D. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-16 · Cited by 118
“Genetic studies revealed allelic segregation of the apolipoprotein E (apoE) gene to families with a higher risk of late-onset AD and of sporadic AD [21-23].”
BackgroundTaubes, A., Nova, P., Zalocusky, K. A., Kosti, I., Bicak, M., Zilberter, M. Y., Hao, Y., Yoon, S. Y., Oskotsky, T., Pineda, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00122-7 · Cited by 118
“4 | Histograms of FC rank changes of human apoE4/4-specific AD signature genes in cell clusters 1, 4, 6, 7, 9–18 in aged apoE4-KI mice. a–n , Histograms of the human apoe4/4-specific transcriptomic signature of AD geneset that was also detected by De analysis of snrNA-seq in the apoe4-KI mouse…”
BackgroundMethodInfluentialSelf-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid
Perugini, M. A., Schuck, P., & Howlett, G. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005565200 · Cited by 118
Association of ALS with head injury, cigarette smoking and APOE genotypes
Schmidt, S., Kwee, L. C., Allen, K. D., & Oddone, E. Z. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.01.011 · Cited by 117
“It is well known that the APOE-4 (ε4) allele is a strong risk factor for AD (29).”
BackgroundCarlo, A.-S., Gustafsen, C., Mastrobuoni, G., Nielsen, M. S., Burgert, T., Hartl, D., Rohe, M., Nykjaer, A., Herz, J., Heeren, J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2425-12.2013 · Cited by 117
“APOE is the most important genetic risk factor for sporadic AD (Corder et al., 1993; Strittmatter et al., 1993).”
BackgroundABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies
Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160467 · Cited by 116
“Genetic studies of sporadic Alzheimer’s disease (AD) and of families with late onset AD revealed that the allele APOE (cid:2) 4 (apoE4) is a genetic risk factor for AD [1–3].”
A search for susceptibility loci for anorexia nervosa: methods and sample description
Kaye, W. H., Lilenfeld, L. R., Berrettini, W. H., Strober, M., Devlin, B., Klump, K. L., Goldman, D., Bulik, C. M., Halmi, K. A., Fichter, M. M., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00240-1 · Cited by 116
“Loci having large, individual effects on liability to complex traits have yet to be identified (see Corder et al 1993; Davies et al 1994; PericakVance et al 1991; Tsai et al 1994 for possible exceptions).”
BackgroundAlzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
“ApoE polymorphisms provide the major genetic risk factor for developing AD (Corder et al. 1993).”
The keystone of Alzheimer pathogenesis might be sought in Aβ physiology
Puzzo, D., Gulisano, W., Arancio, O., & Palmeri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.039 · Cited by 116
“…by APP or PS genes, but apolipoprotein E (APOE) gene, since subjects with the APOE-e4 allele had a more than 10-fold higher risk of dementia (Corder et al., 1993; Slooter et al., 1998); (iv) studies on animal models have demonstrated that if mutations of APP, PS or secretases leading to an…”
Fuentealba, R. A., Liu, Q., Zhang, J., Kanekiyo, T., Hu, X., Lee, J.-M., LaDu, M. J., & Bu, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011884 · Cited by 116
“gene represents the most prevalent genetic risk factor for late-onset AD”
BackgroundFagan, A. M., Murphy, B. A., Patel, S. N., Kilbridge, J. F., Mobley, W. C., Bu, G., & Holtzman, D. M. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6818 · Cited by 116
LRP1 shedding in human brain: roles of ADAM10 and ADAM17
Liu, Q., Zhang, J., Tran, H., Verbeek, M. M., Reiss, K., Estus, S., & Bu, G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-17 · Cited by 116
“LRP1 was shown to bind to apolipoprotein E (apoE) [6] and Aβ, both of which play important roles in the pathogenesis of AD.”
BackgroundBurgess, B. L., McIsaac, S. A., Naus, K. E., Chan, J. Y., Tansley, G. H. K., Yang, J., Miao, F., Ross, C. J. D., van Eck, M., & Hayden, M. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.007 · Cited by 115
Lane-Donovan, C., Wong, W. M., Durakoglugil, M. S., Wasser, C. R., Jiang, S., Xian, X., & Herz, J. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1054-16.2016 · Cited by 115
“The more common ApoE3 allele is considered to be risk neutral, while the relatively rare ApoE2 allele appears to protect against AD (Corder et al., 1994).”
BackgroundEmerging risk of environmental factors: insight mechanisms of Alzheimer’s diseases.
Rahman, M. A., Rahman, M. S., Uddin, M. J., Mamum-Or-Rashid, A. N. M., Pang, M.-G., & Rhim, H. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-08243-z · Cited by 115
Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition
Leonenko, G., Shoai, M., Bellou, E., Sims, R., Williams, J., Hardy, J., Escott‐Price, V., & Initiative, T. A. D. N. (2019) · Annals of Neurology · doi:10.1002/ana.25530 · Cited by 114
LRP in Amyloid‐β Production and Metabolism
BU, G., CAM, J., & ZERBINATTI, C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1377.005 · Cited by 114
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Brodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113
ACAT1/SOAT1 as a Therapeutic Target for Alzheimer's Disease
Shibuya, Y., Chang, C. C., & Chang, T.-Y. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.161 · Cited by 113
Nitsch, R. M., Rebeck, G. W., Deng, M., Richardson, U. I., Tennis, M., Schenk, D. B., Vigo‐Pelfrey, C., Lieberburg, I., Wurtman, R. J., Hyman, B. T., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370414 · Cited by 113
Heffernan, A. L., Chidgey, C., Peng, P., Masters, C. L., & Roberts, B. R. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0804-x · Cited by 113
“ApoE ε4 is recognised as the major single genetic risk factor for developing sporadic forms of AD (Corder et al. 1993).”
BackgroundArdila, A., Lopera, F., Rosselli, M., Moreno, S., Madrigal, L., Arango-Lasprilla, J. C., Arcos, M., Murcia, C., Arango-Viana, J. C., Ossa, J., et al. (2000) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/15.6.515 · Cited by 113
“Differences in the age of onset in the very same family carrying the very same mutation indicates that there are some other nongenetic and/or other genetic factors capable to modify the onset of the disease (Corder et al., 1993; Kehoe et al., 1999; Liao et al., 1998).”
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E., & Goate, A. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.015 · Cited by 111
Toward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress
Gandy, S., & DeKosky, S. T. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092611-084441 · Cited by 110
“In addition to the EOFAD mutations, genetic factors that confer increased risk have been identified, including the most powerful common genetic risk factor, the APOE ε4 allele of apolipoprotein E (APOE), which contributes to approximately 40%– 50% of cases of AD (6).”
BackgroundPeng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
“The APOE type 4 allele (APOE4) is the main genetic risk factor for sporadic AD (64), whereas the APOE2 genotype has been identified as a protective factor for late-onset sporadic AD (63).”
BackgroundImplications of genetic epidemiology for the prevention of substance use disorders
Merikangas, K. R., & Avenevoli, S. (2000) · Addictive Behaviors · doi:10.1016/s0306-4603(00)00129-5 · Cited by 110
Leung, L., Andrews-Zwilling, Y., Yoon, S. Y., Jain, S., Ring, K., Dai, J., Wang, M. M., Tong, L., Walker, D., & Huang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053569 · Cited by 109
Stargardt, A., Swaab, D. F., & Bossers, K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.014 · Cited by 109
“estingly, carriers of the ApoE ε4 variant have 10e30 times a higher risk of developing late-onset sporadic AD (Corder et al., 1993).”
APOE is a major susceptibility gene for Alzheimer’s disease
Roses, A. D., & Saunders, A. M. (1994) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(94)90091-4 · Cited by 108
Self-citationAPOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, C.-C., Murray, M. E., Li, X., Zhao, N., Wang, N., Heckman, M. G., Shue, F., Martens, Y., Li, Y., Raulin, A.-C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9375 · Cited by 108
Gender and age modify the association between APOE and AD-related neuropathology
Ghebremedhin, E., Schultz, C., Thal, D. R., Rüb, U., Ohm, T. G., Braak, E., & Braak, H. (2001) · Neurology · doi:10.1212/wnl.56.12.1696 · Cited by 108
Drug repositioning for Alzheimer’s disease based on systematic “omics” data mining
Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., & Rogaeva, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168812 · Cited by 108
Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides
Ma, J., Brewer, H. B., & Potter, H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00112-1 · Cited by 108
Deeny, S. P., Poeppel, D., Zimmerman, J. B., Roth, S. M., Brandauer, J., Witkowski, S., Hearn, J. W., Ludlow, A. T., Contreras-Vidal, J. L., Brandt, J., et al. (2008) · Biological Psychology · doi:10.1016/j.biopsycho.2008.02.007 · Cited by 107
“Introduction Presence of the ε4 allele of the apolipoprotein E (APOE) gene constitutes a significant risk factor for Alzheimer’s disease (AD) (Corder et al., 1993; Saunders et al., 1993).”
BackgroundZhao, L., Gottesdiener, A. J., Parmar, M., Li, M., Kaminsky, S. M., Chiuchiolo, M. J., Sondhi, D., Sullivan, P. M., Holtzman, D. M., Crystal, R. G., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.020 · Cited by 107
“…fold for heterozygotes and homozygotes, respectively, compared with APOE3 homozygotes) and an earlier age-of-onset for developing the disease (approximately 5 years for each ε4 allele; Corder et al., 1993; Farrer et al., 1997; Lambert et al., 2013; Saunders et al., 1993; Strittmatter et al., 1993).”
Sabbagh, M. N., Lue, L.-F., Fayard, D., & Shi, J. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0069-5 · Cited by 107
“The lifetime risk for developing AD for a patient who is homozygotic for the APOE e4 is 91%, and the lifetime risk for a patient who is heterozygotic for APOE e4 is 47% [37].”
BackgroundHesse, R., Hurtado, M. L., Jackson, R. J., Eaton, S. L., Herrmann, A. G., Colom-Cadena, M., Tzioras, M., King, D., Rose, J., Tulloch, J., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0847-7 · Cited by 107
Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice
Cao, D., Fukuchi, K.-I., Wan, H., Kim, H., & Li, L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.011 · Cited by 106
“Although LDLR genotypes did not affect the expression level of the amyloid- precursor protein transgene, there was a signifi ncrease in A deposition accompanied with an increase of apoE expression in LDLR-deficient Tg2576 mice.”
BackgroundMitochondria, Cybrids, Aging, and Alzheimer's Disease
Swerdlow, R. H., Koppel, S., Weidling, I., Hayley, C., Ji, Y., & Wilkins, H. M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.12.017 · Cited by 106
Li, L., Cao, D., Garber, D. W., Kim, H., & Fukuchi, K.-I. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63572-9 · Cited by 105
“The apolipoprotein (apo) E4 allele is a risk factor for AD as well as cardiovascular diseases.(2) Hypercholesterolemia is an independent risk factor for AD.”
BackgroundLuciano, M., Gow, A. J., Harris, S. E., Hayward, C., Allerhand, M., Starr, J. M., Visscher, P. M., & Deary, I. J. (2009) · Psychology and Aging · doi:10.1037/a0014780 · Cited by 105
“As episodic memory was shown to be especially affected by APOE, Small et al. (2004) suggested that the hippocampus (important in episodic memory) was a major biological target of APOE’s effects, citing prior work in which APOE e4 carriers showed smaller hippocampal volumes than noncarriers (e.g., Cohen, Small, Lalonde…”
BackgroundLee, S.-I., Jeong, W., Lim, H., Cho, S., Lee, H., Jang, Y., Cho, J., Bae, S., Lin, Y.-T., Tsai, L.-H., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.07.017 · Cited by 105
Nilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104
APP Function and Lipids: A Bidirectional Link
Grimm, M. O. W., Mett, J., Grimm, H. S., & Hartmann, T. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00063 · Cited by 104
“The ApoEε4-allele is associated with an increased AD-risk, earlier disease onset and enhanced cerebral plaque load (Corder et al., 1993; Kuusisto et al., 1994; Breitner et al., 1999; Tiraboschi et al., 2004).”
BackgroundSabo, T., Lomnitski, L., Nyska, A., Beni, S., Maronpot, R. R., Shohami, E., Roses, A. D., & Michaelson, D. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00438-3 · Cited by 104
Self-citationOrr, A. L., Kim, C., Jimenez-Morales, D., Newton, B. W., Johnson, J. R., Krogan, N. J., Swaney, D. L., & Mahley, R. W. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181184 · Cited by 103
The cell biology of APOE in the brain
Windham, I. A., & Cohen, S. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.09.004 · Cited by 103
Alfonso, S. I., Callender, J. A., Hooli, B., Antal, C. E., Mullin, K., Sherman, M. A., Lesné, S. E., Leitges, M., Newton, A. C., Tanzi, R. E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf6209 · Cited by 103
Thal, D. R., Papassotiropoulos, A., Saido, T. C., Griffin, W. S. T., Mrak, R. E., Kölsch, H., Tredici, K. D., Attems, J., & Ghebremedhin, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0707-9 · Cited by 103
“The apolipoprotein E (APOE) e4 allele is widely recognized as a risk factor for sporadic AD [8, 19, 62], whereas most other candidate genes remain elusive owing to subsequent replication failure [8].”
BackgroundMicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
ApoE influences regional white-matter axonal density loss in Alzheimer's disease
Slattery, C. F., Zhang, J., Paterson, R. W., Foulkes, A. J. M., Carton, A., Macpherson, K., Mancini, L., Thomas, D. L., Modat, M., Toussaint, N., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.021 · Cited by 102
“In late onset AD (LOAD), APOE ε4 reduces the age of onset (Corder et al., 1993), is associated with medial temporal lobe atrophy (Filippini et al., 2009), and tends to manifest as a ‘typical’ amnestic phenotype (van der Vlies et al., 2007).”
Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease
Beck, J. A. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh134 · Cited by 102
“Inheritance of the APOE E4 allele has been shown to confer increased risk of AD (5,6), but the search for other genes causing sporadic and lateonset AD has been difficult (7).”
BackgroundDolev, I., & Michaelson, D. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404458101 · Cited by 102
The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration
Koldamova, R., Fitz, N. F., & Lefterov, I. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.010 · Cited by 102
Keeney, J. T.-R., Ibrahimi, S., & Zhao, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150348 · Cited by 102
“Humans possess three major genetic isoforms of ApoE coded by three alleles, ε2, ε3, and ε4 [11, 13, 14].”
BackgroundBelinson, H., Lev, D., Masliah, E., & Michaelson, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5633-07.2008 · Cited by 101
“, 1995; Goedert and Spillantini, 2006; Masters and Beyreuther, 2006), and the allele E4 of apolipoprotein E (apoE4), which is the most prevalent genetic risk factor for AD (Corder et al., 1993; Saunders et al., 1993; Roses, 2006).”
BackgroundTransgenic mouse models of Alzheimer’s disease
Janus, C., Chishti, M. A., & Westaway, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00033-8 · Cited by 101
Langbaum, J. B. S., Chen, K., Caselli, R. J., Lee, W., Reschke, C., Bandy, D., Alexander, G. E., Burns, C. M., Kaszniak, A. W., Reeder, S. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.30 · Cited by 100
Nature and Nurture: Genetic and Environmental Influences on Behavior
Plomin, R., & Asbury, K. (2005) · The ANNALS of the American Academy of Political and Social Science · doi:10.1177/0002716205277184 · Cited by 100
“Although the association between APOE allele 4 and LOAD was reported only a decade ago (Corder et al. 1993), much research on dementia now genotypes participants for APOE to ascertain whether results differ for individuals with and without this genetic risk factor (e.”
BackgroundABCA7 frameshift deletion associated with Alzheimer disease in African Americans
Cukier, H. N., Kunkle, B. W., Vardarajan, B. N., Rolati, S., Hamilton-Nelson, K. L., Kohli, M. A., Whitehead, P. L., Dombroski, B. A., Van Booven, D., Lang, R., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000079 · Cited by 100
“APOE was the first gene associated with AD and the e4 allele confers an increased risk across populations.(3,4) Although APOE e4 occurs more frequently in AA than NHW, paradoxically, it has a lower effect”
Liu, D.-S., Pan, X.-D., Zhang, J., Shen, H., Collins, N. C., Cole, A. M., Koster, K. P., Ben Aissa, M., Dai, X.-M., Zhou, M., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0002-2 · Cited by 99
“In AD patients, APOE4 is associated with an earlier age of onset for cognitive deficits than APOE3 [6-11], and possibly a faster rate of cognitive decline [24,25], though results are conflicting regarding the latter.”
BackgroundResultInfluentialReversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease
Xian, X., Pohlkamp, T., Durakoglugil, M. S., Wong, C. H., Beck, J. K., Lane-Donovan, C., Plattner, F., & Herz, J. (2018) · eLife · doi:10.7554/elife.40048 · Cited by 98
“Early work following the seminal discovery of this striking genetic association by the Roses group (Corder et al., 1993) focused on the differential ability of ApoE isoforms to interact with Ab and affect fibril formation.”
BackgroundMulder, M., Jansen, P. J., Janssen, B. J. A., van de Berg, W. D. J., van der Boom, H., Havekes, L. M., de Kloet, R. E., Ramaekers, F. C. S., & Blokland, A. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.015 · Cited by 98
“In humans, one of the three common isoforms of apolipoprotein E (apoE), apoE4, is a major risk factor for Alzheimer's disease (AD) (Corder et al., 1993).”
BackgroundDi Domenico, F., Pupo, G., Giraldo, E., Badìa, M.-C., Monllor, P., Lloret, A., Eugenia Schininà, M., Giorgi, A., Cini, C., Tramutola, A., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.004 · Cited by 97
“One copy of the ApoE2 gene, however, reduces the risk by 60% [11].”
BackgroundGreasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E
Fan, J., Donkin, J., & Wellington, C. (2009) · BioFactors · doi:10.1002/biof.37 · Cited by 97
“Specifically, inheritance of an apoE4 allele increases the risk and reduces the age of onset of AD [42], whereas apoE2 delays onset and reduces risk [43].”
BackgroundApolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice
Knoferle, J., Yoon, S. Y., Walker, D., Leung, L., Gillespie, A. K., Tong, L. M., Bien-Ly, N., & Huang, Y. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2281-14.2014 · Cited by 97
“ApoE4 carriers account for 60 –75% of all AD cases (Farrer et al., 1997), and apoE4 increases the risk of the disease and lowers the age of onset in a gene dose-dependent manner (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993).”
BackgroundReelin protects against amyloid β toxicity in vivo
Lane-Donovan, C., Philips, G. T., Wasser, C. R., Durakoglugil, M. S., Masiulis, I., Upadhaya, A., Pohlkamp, T., Coskun, C., Kotti, T., Steller, L., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aaa6674 · Cited by 96
APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size
Windham, I. A., Powers, A. E., Ragusa, J. V., Wallace, E. D., Zanellati, M. C., Williams, V. H., Wagner, C. H., White, K. K., & Cohen, S. (2024) · Journal of Cell Biology · doi:10.1083/jcb.202305003 · Cited by 96
Zhou, X., Chen, Y., Mok, K. Y., Zhao, Q., Chen, K., Chen, Y., Hardy, J., Li, Y., Fu, A. K. Y., Guo, Q., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715554115 · Cited by 96
“APOE is a well-accepted genetic marker for late-onset AD, and the e4 allele of the APOE gene is the strongest genetic risk factor for the disease (51, 52).”
BackgroundWnt/β-Catenin Signaling in Alzheimer’s Disease
Ferrari, G., Avila, M., Medina, M., Perez-Palma, E., Bustos, B., & Alarcon, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527312666131223113900 · Cited by 95
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95
“To this end, studies have shown that subjects with the APOE ε4/ε4 and ε4/ ε3 genotype are at increased risk for developing late onset AD, whereas the APOE ε2 allele is considered protective [33, 34].”
King, K. S., Kozlitina, J., Rosenberg, R. N., Peshock, R. M., McColl, R. W., & Garcia, C. K. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1926 · Cited by 95
“Variable Value (n = 1960) Age, median (25th-75th percentile), y 50 (42-58)”
MethodApoE and Aβ1–42 Interactions: Effects of Isoform and Conformation on Structure and Function
Manelli, A. M., Stine, W. B., Van Eldik, L. J., & LaDu, M. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:235 · Cited by 95
Age-related accumulation of Reelin in amyloid-like deposits
Knuesel, I., Nyffeler, M., Mormède, C., Muhia, M., Meyer, U., Pietropaolo, S., Yee, B. K., Pryce, C. R., LaFerla, F. M., Marighetto, A., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.011 · Cited by 94
Jendresen, C., Årskog, V., Daws, M. R., & Nilsson, L. N. G. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0835-4 · Cited by 94
“A link between ApoE and Aβ has been found consistently, as APOE dose-dependently enhances the risk of developing late-onset AD and also increases amyloid burden among those carrying ε4 alleles [15, 75].”
BackgroundThe ApoE receptors Vldlr and Apoer2 in central nervous system function and disease
Lane-Donovan, C., & Herz, J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075507 · Cited by 94
“14 three-fold, and two copies increasing risk 12-fold (76).”
BackgroundThe role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94
TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism
Zheng, H., Cheng, B., Li, Y., Li, X., Chen, X., & Zhang, Y.-W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00395 · Cited by 94
Genetics of human longevity within an eco-evolutionary nature-nurture framework
Giuliani, C., Garagnani, P., & Franceschi, C. (2018) · Circulation Research · doi:10.1161/circresaha.118.312562 · Cited by 92
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease
Le Guen, Y., Belloy, M. E., Grenier-Boley, B., de Rojas, I., Castillo-Morales, A., Jansen, I., Nicolas, A., Bellenguez, C., Dalmasso, C., Küçükali, F., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1166 · Cited by 93
“21 gnomAD22 database–derived information was used to filter out SNVs that met one of the following exclusion criteria23,24: (1) located in a low-complexity region, (2) located within common structural variants (MAF greater than 1%), (3) multiallelic SNVs with MAF greater than 1% for at least 2 alternate alleles, (4) l…”
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.